Title |
Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes
|
---|---|
Published in |
Journal of Neuro-Oncology, August 2018
|
DOI | 10.1007/s11060-018-2966-6 |
Pubmed ID | |
Authors |
Zixuan Yuan, Liang Zhao, Yafei Zhang, Shun Li, Bomin Pan, Lei Hua, Zhen Wang, Chengkun Ye, Jun Lu, Rutong Yu, Hongmei Liu |
Abstract |
GOLPH3 has been shown to be involved in glioma proliferation. In this study, we aimed to demonstrate that GOLPH3 can serve as a target for glioma gene therapy. During the experiment, cationic liposomes with angiopep-2 (A2-CL) were used to deliver siGOLPH3 crossing the blood-brain barrier and reaching the glioma. At the cellular level, the A2-CL/siGOLPH3 could silence GOLPH3 and then effectively inhibited the proliferation of cells. In vivo experiments, using U87-GFP-Luci-bearing BALB/c mouse models, we demonstrated that A2-CL could deliver GOLPH3-siRNA specifically to glioma and effectively inhibit glioma growth. This study shows that GOLPH3 has great potential as a target for the gene therapy of glioma and is of great value in precise medical applications. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 43% |
United Kingdom | 1 | 14% |
Unknown | 3 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 43% |
Science communicators (journalists, bloggers, editors) | 3 | 43% |
Scientists | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 29 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 28% |
Student > Bachelor | 4 | 14% |
Student > Ph. D. Student | 4 | 14% |
Professor | 1 | 3% |
Unspecified | 1 | 3% |
Other | 1 | 3% |
Unknown | 10 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
Neuroscience | 3 | 10% |
Biochemistry, Genetics and Molecular Biology | 3 | 10% |
Chemical Engineering | 2 | 7% |
Chemistry | 2 | 7% |
Other | 2 | 7% |
Unknown | 14 | 48% |